Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium.

Lagergren K, Ek WE, Levine D, Chow WH, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ, Corley DA, Hardie LJ, Wu AH, Fitzgerald RC, Pharoah P, Caldas C, Romero Y, Vaughan TL, MacGregor S, Whiteman D, Westberg L, Nyren O, Lagergren J.

PLoS One. 2015 Sep 25;10(9):e0138738. doi: 10.1371/journal.pone.0138738. eCollection 2015.

2.

Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J.

Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12.

3.

Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.

Ek WE, Lagergren K, Cook M, Wu AH, Abnet CC, Levine D, Chow WH, Bernstein L, Risch HA, Shaheen NJ, Bird NC, Corley DA, Hardie LJ, Fitzgerald RC, Gammon MD, Romero Y, Liu G, Ye W, Vaughan TL, MacGregor S, Whiteman DC, Westberg L, Lagergren J.

Int J Cancer. 2016 Mar 1;138(5):1146-52. doi: 10.1002/ijc.29863. Epub 2015 Oct 5.

4.

Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma.

Drovdlic CM, Goddard KA, Chak A, Brock W, Chessler L, King JF, Richter J, Falk GW, Johnston DK, Fisher JL, Grady WM, Lemeshow S, Eng C.

J Med Genet. 2003 Sep;40(9):651-6. Erratum in: J Med Genet. 2004 Jan;41(1):46.

5.

Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma.

Menke V, Pot RG, Moons LM, van Zoest KP, Hansen B, van Dekken H, Siersema PD, Kusters JG, Kuipers EJ.

J Hum Genet. 2012 Jan;57(1):26-32. doi: 10.1038/jhg.2011.124. Epub 2011 Dec 1.

PMID:
22129558
6.

Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP.

Gastroenterology. 2018 Apr;154(5):1273-1281.e3. doi: 10.1053/j.gastro.2017.12.003. Epub 2017 Dec 13.

PMID:
29247777
7.

Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.

Holmberg D, Ness-Jensen E, Mattsson F, El-Serag HB, Lagergren J.

Eur J Cancer. 2017 Apr;75:41-46. doi: 10.1016/j.ejca.2016.12.037. Epub 2017 Feb 17.

PMID:
28214656
8.

MIC-1/GDF15 in Barrett's oesophagus and oesophageal adenocarcinoma.

Fisher OM, Levert-Mignon AJ, Lord SJ, Lee-Ng KK, Botelho NK, Falkenback D, Thomas ML, Bobryshev YV, Whiteman DC, Brown DA, Breit SN, Lord RV.

Br J Cancer. 2015 Apr 14;112(8):1384-91. doi: 10.1038/bjc.2015.100. Epub 2015 Mar 17.

9.

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.

Masclee GM, Coloma PM, de Wilde M, Kuipers EJ, Sturkenboom MC.

Aliment Pharmacol Ther. 2014 Jun;39(11):1321-30. doi: 10.1111/apt.12759. Epub 2014 Apr 16.

10.

NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.

Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC.

BMJ Open. 2015 Jan 29;5(1):e006640. doi: 10.1136/bmjopen-2014-006640.

11.

The evolution and outcome of surveillance of Barrett's oesophagus over four decades in a UK District General Hospital.

Royston C, Caygill C, Charlett A, Bardhan KD.

Eur J Gastroenterol Hepatol. 2016 Dec;28(12):1365-1373.

PMID:
27571366
12.

The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma.

den Hoed CM, van Blankenstein M, Dees J, Kuipers EJ.

Br J Cancer. 2011 Jul 12;105(2):200-5. doi: 10.1038/bjc.2011.214. Epub 2011 Jun 14.

13.

Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis.

Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB.

Gut. 2014 Aug;63(8):1229-37. doi: 10.1136/gutjnl-2013-305997. Epub 2013 Nov 12. Review.

14.

Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.

Bhat SK, McManus DT, Coleman HG, Johnston BT, Cardwell CR, McMenamin U, Bannon F, Hicks B, Kennedy G, Gavin AT, Murray LJ.

Gut. 2015 Jan;64(1):20-5. doi: 10.1136/gutjnl-2013-305506. Epub 2014 Apr 3.

PMID:
24700439
15.

Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM.

Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. Epub 2016 Aug 2.

16.

MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium.

Buas MF, Onstad L, Levine DM, Risch HA, Chow WH, Liu G, Fitzgerald RC, Bernstein L, Ye W, Bird NC, Romero Y, Casson AG, Corley DA, Shaheen NJ, Wu AH, Gammon MD, Reid BJ, Hardie LJ, Peters U, Whiteman DC, Vaughan TL.

PLoS One. 2015 Jun 3;10(6):e0128617. doi: 10.1371/journal.pone.0128617. eCollection 2015.

17.

The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis.

Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW.

Gut. 2012 Jul;61(7):970-6. doi: 10.1136/gutjnl-2011-300730. Epub 2011 Oct 13.

PMID:
21997553
18.

Adam, Eve and the reflux enigma: age and sex differences across the gastro-oesophageal reflux spectrum.

Royston C, Bardhan KD.

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):634-639. doi: 10.1097/MEG.0000000000000845.

PMID:
28151751
19.

Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

O'Rorke MA, Cantwell MM, Abnet CC, Brockman AJ, Murray LJ; FINBAR Study Group.

Int J Cancer. 2012 Oct 15;131(8):1882-91. doi: 10.1002/ijc.27434. Epub 2012 Mar 6.

20.

Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.

Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ; ProBar-Study Group.

Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802. Epub 2015 Apr 22.

PMID:
25903690

Supplemental Content

Support Center